Natalizumab High Titer Immunogenicity and Safety
NCT00516893
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
113
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL:
BG00002-E (natalizumab high titer)
Sponsor
Biogen
Collaborators
[object Object]